No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
BlackRock Adjusts Holdings in MaxCyte, Inc.
TD Cowen Maintains MaxCyte(MXCT.US) With Buy Rating
Home Healthcare Inflation Is Stubbornly High -- WSJ
Express News | MaxCyte, Inc. MaxCyte, Inc. - Mxcr - Strategic Platform License With TG Therapeutics
MaxCyte Signs Strategic Platform License With TG Therapeutics to Advance Its Autoimmune Cell Therapeutics Programs
MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference